Rationally Engineered Adenosine A2A Decoy Receptor for Reversing Immunosuppression of Breast Cancer.

Area of Science:

• Immunology
• Biotechnology
• Materials Science

Background:

• The hypoxia-adenosine axis promotes tumor immune evasion via adenosine A2A receptor (A2AR) activation.
• Current small-molecule A2AR antagonists have limitations like short half-life and off-target effects.
• Solid tumor physical barriers impede effective immune-mediated tumor cell killing.

Purpose of the Study:

• To develop a novel protein inhibitor targeting the adenosine-A2AR axis.
• To create a drug delivery system capable of remodeling the tumor microenvironment.
• To establish a dual-targeted therapeutic strategy for solid tumors.

Main Methods:

• Design and characterization of A2AR^QTY-Fc, a high-affinity adenosine-A2AR protein inhibitor.
• Development of a keratin hydrogel drug delivery system for A2AR^QTY-Fc.
• Evaluation of the combined therapy in a 4T1 breast cancer mouse model.

Main Results:

• A2AR^QTY-Fc demonstrated high binding affinity, stability, and effectively blocked T cell A2AR signaling.
• Keratin hydrogel delivery of A2AR^QTY-Fc significantly inhibited tumor growth in vivo.
• The treatment reduced extracellular matrix density and increased immune cell infiltration.

Conclusions:

• The A2AR^QTY-Fc protein inhibitor effectively targets the immunosuppressive hypoxia-adenosine axis.
• Keratin hydrogel delivery physically remodels the tumor microenvironment, enhancing therapeutic efficacy.
• This dual-targeted approach offers a promising paradigm for overcoming GPCR-mediated immune evasion and matrix barriers in solid tumors.